In a conversation during the 2022 American Society of Hematology Annual Meeting, an expert from the University of Texas MD Anderson Cancer Center, spoke to how treatments have improved for patients with mantle cell lymphoma.
Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center.
Harry P. Erba, MD, PhD, highlights key data on ziftomenib in patients with relapsed/refractory acute myeloid leukemia and its potential as part of a combination regimen.
According to the phase 3 PERSIST-1 trial and PAC203 trial, thrombocytopenia was associated with myelofibrosis treatment.
Patients with IDH1-mutant relapsed/refractory acute myeloid leukemia achieved a notable complete response rate following treatment with olutasidenib.
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma achieved promising early responses following treatment with BCB-11417 with or without zanubrutinib.
BCMA/CD19 dual-targeting FasTCAR-T Cells resulted in an overall response rate of 100% among patients with multiple myeloma, with all evaluable patients showing MRD negativity to 12 months.
Real-world data associate axicabtagene ciloleucel with temporarily worse quality of life in patients with diffuse large B cell lymphoma, transformed follicular lymphoma, or follicular lymphoma, which improves within 1-year post-infusion.
Patients with myelofibrosis and anemia who were previously treated with a JAK inhibitor experienced durable responses up to 48 weeks with momelotinib.
Treatment with induction and maintenance ibrutinib combined with chemoimmunotherapy and autologous stem cell transplant resulted in statistically significantly improved outcomes in a younger population with mantle cell lymphoma.